Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
3 "Area under the curve"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Clinical Care/Education
Comparison of Glucose Area Under the Curve Measured Using Minimally Invasive Interstitial Fluid Extraction Technology with Continuous Glucose Monitoring System in Diabetic Patients
Mei Uemura, Yutaka Yano, Toshinari Suzuki, Taro Yasuma, Toshiyuki Sato, Aya Morimoto, Samiko Hosoya, Chihiro Suminaka, Hiromu Nakajima, Esteban C. Gabazza, Yoshiyuki Takei
Diabetes Metab J. 2017;41(4):265-274.   Published online July 31, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.4.265
  • 6,005 View
  • 63 Download
  • 4 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   
Background

Continuous glucose monitoring (CGM) is reported to be a useful technique, but difficult or inconvenient for some patients and institutions. We are developing a glucose area under the curve (AUC) monitoring system without blood sampling using a minimally invasive interstitial fluid extraction technology (MIET). Here we evaluated the accuracy of interstitial fluid glucose (IG) AUC measured by MIET in patients with diabetes for an extended time interval and the potency of detecting hyperglycemia using CGM data as a reference.

Methods

Thirty-eight inpatients with diabetes undergoing CGM were enrolled. MIET comprised a pretreatment step using a plastic microneedle array and glucose accumulation step with a hydrogel patch, which was placed on two sites from 9:00 AM to 5:00 PM or from 10:00 PM to 6:00 AM. IG AUC was calculated by accumulated glucose extracted by hydrogel patches using sodium ion as standard.

Results

A significant correlation was observed between the predicted AUC by MIET and CGM in daytime (r=0.76) and nighttime (r=0.82). The optimal cutoff for the IG AUC value of MIET to predict hyperglycemia over 200 mg/dL measured by CGM for 8 hours was 1,067.3 mg·hr/dL with 88.2% sensitivity and 81.5% specificity.

Conclusion

We showed that 8-hour IG AUC levels using MIET were valuable in estimating the blood glucose AUC without blood sampling. The results also supported the concept of using this technique for evaluating glucose excursion and for screening hyperglycemia during 8 hours in patients with diabetes at any time of day.

Citations

Citations to this article as recorded by  
  • Efficacy of Postprandial Exercise in Mitigating Glycemic Responses in Overweight Individuals and Individuals with Obesity and Type 2 Diabetes—A Systematic Review and Meta-Analysis
    Jie Kang, Brian M. Fardman, Nicholas A. Ratamess, Avery D. Faigenbaum, Jill A. Bush
    Nutrients.2023; 15(20): 4489.     CrossRef
  • Multifunctional Wearable System that Integrates Sweat‐Based Sensing and Vital‐Sign Monitoring to Estimate Pre‐/Post‐Exercise Glucose Levels
    Yongseok Joseph Hong, Hyunjae Lee, Jaemin Kim, Minha Lee, Hyung Jin Choi, Taeghwan Hyeon, Dae‐Hyeong Kim
    Advanced Functional Materials.2018;[Epub]     CrossRef
Others
Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring
Satoshi Ugi, Hiroshi Maegawa, Katsutaro Morino, Yoshihiko Nishio, Toshiyuki Sato, Seiki Okada, Yasuo Kikkawa, Toshihiro Watanabe, Hiromu Nakajima, Atsunori Kashiwagi
Diabetes Metab J. 2016;40(4):326-333.   Published online July 26, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.4.326
  • 7,982 View
  • 95 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

Management of postprandial hyperglycemia is a key aspect in diabetes treatment. We developed a novel system to measure glucose area under the curve (AUC) using minimally invasive interstitial fluid extraction technology (MIET) for simple monitoring of postprandial glucose excursions. In this study, we evaluated the relationship between our system and continuous glucose monitoring (CGM) by comparing glucose AUC obtained using MIET with that obtained using CGM for a long duration.

Methods

Twenty diabetic inpatients wearing a CGM system were enrolled. For MIET measurement, a plastic microneedle array was applied to the skin as pretreatment, and hydrogels were placed on the pretreated area to collect interstitial fluid. Hydrogels were replaced every 2 or 4 hours and AUC was predicted on the basis of glucose and sodium ion levels.

Results

AUC predicted by MIET correlated well with that measured by CGM (r=0.93). Good performances of both consecutive 2- and 4-hour measurements were observed (measurement error: 11.7%±10.2% for 2 hours and 11.1%±7.9% for 4 hours), indicating the possibility of repetitive measurements up to 8 hours. The influence of neither glucose fluctuation nor average glucose level over the measurement accuracy was observed through 8 hours.

Conclusion

Our system showed good relationship with AUC values from CGM up to 8 hours, indicating that single pretreatment can cover a large portion of glucose excursion in a day. These results indicated possibility of our system to contribute to convenient monitoring of glucose excursions for a long duration.

Citations

Citations to this article as recorded by  
  • Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study
    Pin‐Lun Tsai, Chia‐Hung Lin, Yu‐Yao Huang, Hsin‐Yun Chen, Yi‐Hsuan Lin
    The Kaohsiung Journal of Medical Sciences.2024; 40(12): 1086.     CrossRef
  • Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial
    Doortje Rademaker, Anne W. T. van der Wel, Rik van Eekelen, Daphne N. Voormolen, Harold W. de Valk, Inge M. Evers, Ben Willem Mol, Arie Franx, Sarah E. Siegelaar, Bas B. van Rijn, J. Hans DeVries, Rebecca C. Painter
    Diabetes, Obesity and Metabolism.2023; 25(12): 3798.     CrossRef
  • Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
    Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, Hsin-Yun Chen, An-Shun Tai, Shih-Chen Fu, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Sheng-Hsuan Lin
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • Advantages of Applying Artificial Intelligent System to Medical Neurology (Preprint)
    Zhenqiang Fu, Jingtao Wang, Jingtao Wang
    JMIR Medical Informatics.2020;[Epub]     CrossRef
  • Comparison of Glucose Area Under the Curve Measured Using Minimally Invasive Interstitial Fluid Extraction Technology with Continuous Glucose Monitoring System in Diabetic Patients
    Mei Uemura, Yutaka Yano, Toshinari Suzuki, Taro Yasuma, Toshiyuki Sato, Aya Morimoto, Samiko Hosoya, Chihiro Suminaka, Hiromu Nakajima, Esteban C. Gabazza, Yoshiyuki Takei
    Diabetes & Metabolism Journal.2017; 41(4): 265.     CrossRef
Randomized Controlled Trial
Short-term Therapeutic Efficacy of Different Oral Hypoglycemic Agents Combined with Once Daily Insulin Glargine in Type 2 Diabetic Subjects with Failure of Sulfonylurea and Metformin Combination.
Seong Il Hong, Hyeong Jin Kim, Jong Myon Bae, Sun Ok Song, Kyung Suk Park, Byung Soo Jeon, Seun Duk Hwang, Jin Yi Choi, Jeong Hun Kim, Hyuk Jin Kwon, Ja Sung Choi, Myoung Lyeol Woo, Ji Hoon Cho, Young Jun Won
Korean Diabetes J. 2007;31(4):336-342.   Published online July 1, 2007
DOI: https://doi.org/10.4093/jkda.2007.31.4.336
  • 2,446 View
  • 23 Download
AbstractAbstract PDF
Backgroud: Although the extended duration of action of insulin glargine supports a convenient once daily injection, the combination with other short acting insulins or oral hypoglycemic agents is required to control postprandial hyperglycemia in type 2 diabetes. The present study was designed to compare the short-term therapeutic efficacy of oral hypoglycemic agents with once daily insulin glargine, switching from a multiple daily injection regimen. METHODS: After control with the intensive regimen (daily lispro insulin and glargine) during 5~7 days, 80 in-patients with type 2 diabetes were randomized and treated with four oral hypoglycemic agents (glimepiride 4 mg qd, metformin 500 mg bid, nateglinide 90 mg tid, or acarbose 100 mg tid) plus once daily insulin glargine during 5 days. Blood glucose concentration was recorded by seven daily estimations (before each meal, 2 hours after each meal, and bedtime). Blood glucose concentrations and area under the curves (AUCs) of blood glucose were compared among four groups. RESULTS: The area under the curve of blood glucose of metformin, glimepiride, nateglinide, and acarbose groups were 165.5 +/- 46.0, 178.5 +/- 36.5, 209.9 +/- 55.1, and 224.9 +/- 55.8 mmol/L/hr respectively. Blood glucose concentrations and area under the curves of blood glucose of glimepiride and metformin groups were significantly lower than those of acarbose group. Also, those of metformin group were significantly lower than those of nateglinide group. Conclusions: Metformin or glimepiride are more effective oral hypoglycemic agent than nateglinide or acarbose in the combination with insulin glargine in type 2 diabetic subjects with failure of sulfonylurea and metformin combination.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP